ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy

动脉网12-16

ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592514799?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-16 14:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2592514799","market":"us","top_or_hot":-1,"title":"ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy","media":"动脉网","content":"<div>\n<p>ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议，涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-16 14:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b","article_id":"2592514799","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216144226a6a844ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592514799","pubTimestamp":1765867260,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"The total potential value of the agreement is up to $1.04 billion. ADEL will receive a non-refundable upfront payment of $80 million and is eligible to receive additional payments contingent upon the achievement of specified development and commercial milestones. Additionally, ADEL is entitled to receive tiered royalties on net sales ranging up to double-digit percentages..协议的总潜在价值高达 10.4 亿美元。ADEL spearheaded the entire discovery and preclinical development of ADEL-Y01 using its proprietary neural disease research and development platform. Since 2020, ADEL has been co-developing the asset through a joint research and development agreement with Oscotec Inc. Currently, ADEL-Y01 is undergoing a global Phase 1 clinical trial  under an Investigational New Drug  application approved by the U.S.ADEL利用其专有的神经疾病研发平台，引领了ADEL-Y01的整个发现和临床前开发过程。自2020年起，ADEL通过与Oscotec Inc.签订的联合研发协议共同开发该资产。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","GCVRZ":"Sanofi","SNYNF":"Sanofi"},"translate_title":"ADEL signs a $1.04 billion global licensing agreement with Sanofi for novel investigational therapies for Alzheimer's disease ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"GCVRZ":1.5},"content_text":"ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a multinational healthcare company, for the development and commercialization of ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease, and related backup compounds..ADEL公司是一家致力于开发治疗阿尔茨海默病等神经退行性疾病疗法的生物制药公司，该公司今日宣布已与跨国医疗保健公司赛诺菲达成一项独家全球许可协议，以开发和商业化潜在的首创阿尔茨海默病抗体疗法ADEL-Y01及其相关备用化合物。The total potential value of the agreement is up to $1.04 billion. ADEL will receive a non-refundable upfront payment of $80 million and is eligible to receive additional payments contingent upon the achievement of specified development and commercial milestones. Additionally, ADEL is entitled to receive tiered royalties on net sales ranging up to double-digit percentages..协议的总潜在价值高达 10.4 亿美元。ADEL 将获得 8000 万美元的不可退还的首付款，并有资格在达成特定开发和商业里程碑后获得额外付款。此外，ADEL 还有权获得按净销售额计算的阶梯式专利使用费，比例最高可达两位数百分比。ADEL-Y01 is a humanized monoclonal antibody that selectively targets tau protein acetylated at Lysine-280 (acK280). Unlike therapies targeting total tau, ADEL-Y01 specifically inhibits the aggregation and propagation of toxic tau species—a key driver of Alzheimer's pathology—while preserving the function of normal microtubule-associated tau..ADEL-Y01 是一种人源化单克隆抗体，可选择性靶向在赖氨酸 280（acK280）位点乙酰化的 tau 蛋白。与靶向总 tau 的疗法不同，ADEL-Y01 专门抑制有毒 tau 物种的聚集和传播——这是阿尔茨海默病病理的关键驱动因素——同时保留正常微管相关 tau 的功能。ADEL spearheaded the entire discovery and preclinical development of ADEL-Y01 using its proprietary neural disease research and development platform. Since 2020, ADEL has been co-developing the asset through a joint research and development agreement with Oscotec Inc. Currently, ADEL-Y01 is undergoing a global Phase 1 clinical trial (First-in-human study) under an Investigational New Drug (IND) application approved by the U.S.ADEL利用其专有的神经疾病研发平台，引领了ADEL-Y01的整个发现和临床前开发过程。自2020年起，ADEL通过与Oscotec Inc.签订的联合研发协议共同开发该资产。目前，ADEL-Y01正在美国批准的研究性新药（IND）申请下进行全球I期临床试验（首次人体研究）。FDA..食品药品监督管理局。。'This strategic partnership with Sanofi, a global leader in healthcare,  underscores ADEL's technological strength and highlights the therapeutic promise of ADEL-Y01,' said Seung-Yong Yoon, CEO of ADEL. 'By combining our scientific expertise with the proven development and commercialization capabilities of Sanofi, we hope to accelerate the delivery of this disease-modifying therapy to people living with Alzheimer's around the world.'.“与全球医疗保健领域的领导者赛诺菲达成这一战略合作伙伴关系，彰显了ADEL的技术实力，并突显了ADEL-Y01的治疗潜力，”ADEL首席执行官尹承勇表示。“通过将我们的科学专业知识与赛诺菲经过验证的开发和商业化能力相结合，我们希望能够加速将这种疾病修饰疗法带给全球的阿尔茨海默病患者。”'Erik Wallstroem, Global Head of Multiple Sclerosis, Neurology and Gene Therapy Development, Sanofi, commented: 'ADEL's innovative approach to targeting tau acetylation offers a promising and differentiated mechanism for addressing the underlying causes of Alzheimer's disease. We look forward to advancing ADEL-Y01 through clinical development to provide new hope for patients living with this devastating condition.''.赛诺菲全球多发性硬化症、神经学和基因治疗开发负责人埃里克·瓦尔斯特罗姆评论道：“ADEL针对tau乙酰化的创新方法为解决阿尔茨海默病的根本原因提供了一个有前景且独特的机制。我们期待推动ADEL-Y01的临床开发，为受这一毁灭性疾病影响的患者带来新希望。”About ADEL, Inc.关于ADEL公司Founded in 2016 by Professor Seung-Yong Yoon of Asan Medical Center, University of Ulsan College of Medicine, ADEL, Inc. is a biotech company developing therapeutics for neurodegenerative diseases. Leveraging a proprietary platform that targets disease-relevant protein modifications and aggregation, ADEL has built a robust pipeline including ADEL-Y01, and is advancing toward global leadership in the field..ADEL公司成立于2016年，由蔚山大学医学院、首尔峨山医院的尹承龙教授创立，是一家致力于开发神经退行性疾病治疗药物的生物技术公司。ADEL依托其针对疾病相关蛋白修饰和聚集的专有平台，构建了包括ADEL-Y01在内的强大研发管线，并正朝着在全球领域内占据领导地位的目标迈进。Source: prnewswire.com来源：prnewswire.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592514799","isCrawlerRequest":true}